Truist Financial Reiterates “Buy” Rating for Eli Lilly and Company (NYSE:LLY)

Eli Lilly and Company (NYSE:LLY)‘s stock had its “buy” rating reiterated by investment analysts at Truist Financial in a research report issued on Monday,MarketScreener reports.

Other analysts have also recently issued research reports about the company. Guggenheim lowered their price target on Eli Lilly and Company from $1,163.00 to $1,161.00 and set a “buy” rating on the stock in a report on Tuesday, January 20th. Loop Capital set a $1,200.00 price objective on shares of Eli Lilly and Company in a research report on Tuesday, February 10th. Morgan Stanley raised their target price on shares of Eli Lilly and Company from $1,290.00 to $1,313.00 and gave the company an “overweight” rating in a research note on Thursday, February 5th. Deutsche Bank Aktiengesellschaft boosted their price target on shares of Eli Lilly and Company from $1,200.00 to $1,285.00 and gave the stock a “buy” rating in a research note on Monday, February 9th. Finally, TD Cowen increased their price target on shares of Eli Lilly and Company from $960.00 to $1,250.00 and gave the stock a “buy” rating in a report on Thursday, January 29th. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and five have given a Hold rating to the stock. Based on data from MarketBeat.com, Eli Lilly and Company has a consensus rating of “Moderate Buy” and a consensus target price of $1,229.33.

Eli Lilly and Company Price Performance

NYSE:LLY traded down $2.47 during trading hours on Monday, hitting $1,039.68. The stock had a trading volume of 423,379 shares, compared to its average volume of 3,305,907. The company has a 50 day simple moving average of $1,054.49 and a two-hundred day simple moving average of $923.72. The firm has a market capitalization of $980.79 billion, a price-to-earnings ratio of 45.61, a P/E/G ratio of 1.23 and a beta of 0.39. The company has a debt-to-equity ratio of 1.54, a current ratio of 1.58 and a quick ratio of 1.19. Eli Lilly and Company has a one year low of $623.78 and a one year high of $1,133.95.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Wednesday, February 4th. The company reported $7.54 earnings per share for the quarter, topping the consensus estimate of $7.48 by $0.06. The firm had revenue of $19.29 billion for the quarter, compared to analysts’ expectations of $17.85 billion. Eli Lilly and Company had a net margin of 31.66% and a return on equity of 102.94%. The business’s quarterly revenue was up 42.6% on a year-over-year basis. During the same quarter in the prior year, the firm posted $5.32 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. Research analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the stock. Exencial Wealth Advisors LLC lifted its holdings in Eli Lilly and Company by 189.6% in the 3rd quarter. Exencial Wealth Advisors LLC now owns 17,408 shares of the company’s stock worth $13,283,000 after purchasing an additional 11,396 shares in the last quarter. Rede Wealth LLC purchased a new position in Eli Lilly and Company in the third quarter worth about $487,000. Central Pacific Bank Trust Division raised its holdings in Eli Lilly and Company by 25.8% during the 3rd quarter. Central Pacific Bank Trust Division now owns 8,990 shares of the company’s stock valued at $6,859,000 after buying an additional 1,843 shares during the period. Cidel Asset Management Inc. boosted its stake in shares of Eli Lilly and Company by 26.5% during the 3rd quarter. Cidel Asset Management Inc. now owns 26,726 shares of the company’s stock worth $20,392,000 after purchasing an additional 5,591 shares during the period. Finally, Oak Family Advisors LLC purchased a new stake in shares of Eli Lilly and Company in the third quarter worth approximately $1,979,000. 82.53% of the stock is owned by institutional investors.

Key Headlines Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Rival trial setback reinforces Lilly’s lead in obesity drugs — Novo’s CagriSema failed to match tirzepatide in an 84‑week head‑to‑head, bolstering expectations that Lilly’s Zepbound/Mounjaro will maintain market share and pricing power. Read More.
• Positive Sentiment: Zepbound multi‑dose pen approval improves patient convenience and retention — FDA OK for a multi‑dose weekly pen reduces switching friction and could support longer treatment duration and recurring revenue. Read More.
• Positive Sentiment: Analyst and pipeline support — Wall Street firms (e.g., Goldman) are keeping bullish views and high price targets, and Lilly reported additional positive trial/licensing updates that underscore long‑term growth beyond GLP‑1s. Read More.
• Neutral Sentiment: Product strategy to boost retention — Lilly’s multi‑dose pen and other convenience moves aim to reduce refill churn; execution matters but the strategic intent is positive for long‑term demand. Read More.
• Negative Sentiment: Novo’s planned U.S. list‑price cuts (up to ~50%) for Ozempic/Wegovy create pricing tailwinds for patients but pose clear competitive pricing pressure across the GLP‑1 market that could compress Lilly’s realized prices and near‑term revenue. Read More.
• Negative Sentiment: Market reaction and investor worry over revenue impact — After Novo’s price‑cut plans surfaced, Lilly shares showed short‑term weakness as investors price in potential margin/market‑share shifts despite the trial win. Read More.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.